SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-190078
Filing Date
2020-07-09
Accepted
2020-07-09 07:30:52
Documents
8
Period of Report
2020-07-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d936842d8k.htm 8-K 31754
2 EX-10.1 d936842dex101.htm EX-10.1 7825
3 EX-10.2 d936842dex102.htm EX-10.2 32959
4 EX-10.3 d936842dex103.htm EX-10.3 41236
5 EX-10.4 d936842dex104.htm EX-10.4 45782
6 EX-99.1 d936842dex991.htm EX-99.1 11766
7 GRAPHIC g936842akcea.jpg GRAPHIC 4349
8 GRAPHIC g936842g03b19.jpg GRAPHIC 5957
  Complete submission text file 0001193125-20-190078.txt   187099
Mailing Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210
Business Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210 617-207-0202
AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)

IRS No.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38137 | Film No.: 201019533
SIC: 2834 Pharmaceutical Preparations